List of Excipients in Branded Drug LISINOPRIL WITH HYDROCHLOROTHIAZIDE

Generic Drugs Containing LISINOPRIL WITH HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	lisinopril and hydrochlorothiazide	0143-1262	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Hikma Pharmaceuticals USA Inc	lisinopril and hydrochlorothiazide	0143-1262	FD&C BLUE NO. 2
Hikma Pharmaceuticals USA Inc	lisinopril and hydrochlorothiazide	0143-1262	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	lisinopril and hydrochlorothiazide	0143-1262	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	lisinopril and hydrochlorothiazide	0143-1262	MANNITOL

What are the Most Frequently-Used Excipients in LISINOPRIL WITH HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
5	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
3	FD&C BLUE NO. 2
2	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW

Lisinopril With Hydrochlorothiazide: Excipient Strategy, Patent Status, and Commercial Opportunities

Last updated: August 24, 2026

Lisinopril/hydrochlorothiazide is a mature, multisource fixed-dose antihypertensive combination with limited active-ingredient patent protection. Commercial differentiation depends primarily on manufacturing cost, tablet robustness, dissolution control, packaging, supply reliability, and patient-friendly formulations rather than exclusivity.

The combination contains the ACE inhibitor lisinopril and the thiazide diuretic hydrochlorothiazide (HCTZ). Common strengths include 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg tablets. The product is generally marketed as an immediate-release oral tablet through abbreviated new drug applications (ANDAs) and equivalent non-U.S. regulatory pathways.

What is the regulatory status of lisinopril/hydrochlorothiazide?

Lisinopril/hydrochlorothiazide is an FDA-approved fixed-dose combination available from multiple generic manufacturers. The original branded product, Zestoretic, was marketed by Merck. The product is not a biologic and does not create biosimilar exposure.

FDA pathway and Orange Book status

The commercial product is generally pursued through the ANDA pathway because the reference product has established safety, efficacy, dosage form, strength, and bioequivalence standards. The Orange Book lists approved products and patent or exclusivity information for FDA-approved drugs.[1]

Regulatory issue	Commercial assessment
Dosage form	Immediate-release tablet
Route	Oral
FDA pathway for generics	ANDA
Reference brand	Zestoretic
Active ingredients	Lisinopril and hydrochlorothiazide
Biosimilar risk	None
New chemical entity exclusivity	Expired
Current commercial barrier	Low active-ingredient exclusivity; execution and scale matter more
Orange Book relevance	Product approval and any listed patents or exclusivity

Because both active ingredients and the fixed-dose combination have been marketed for decades, there is no practical new-drug exclusivity barrier for standard tablets. Regulatory value is concentrated in formulation quality, bioequivalence, manufacturing controls, and supply-chain performance.

What patents protect lisinopril/hydrochlorothiazide?

The principal composition-of-matter and early product patents associated with lisinopril, HCTZ, and the original combination expired years ago. Standard generic tablets therefore face little meaningful patent risk from the core active ingredients.

Patent expiration and Paragraph IV risk

The original lisinopril patent estate dates to the early development of lisinopril and related ACE-inhibitor technology. Core patents associated with the molecule and the original fixed-dose product are expired. HCTZ is an older thiazide diuretic with no meaningful current composition-of-matter exclusivity.

For a conventional lisinopril/HCTZ tablet, a Paragraph IV certification is generally not the central market-access issue because there is no significant active patent barrier comparable to a recently approved branded product. A generic applicant may still review Orange Book listings and certify against any listed patents, but commercial launch risk is primarily tied to approval timing, manufacturing readiness, pricing, and market-share acquisition.

Are formulation patents still important?

Formulation patents can matter if a company develops a materially different delivery system, including:

• Orally disintegrating tablets.
• Taste-masked or rapidly dispersible tablets.
• Modified-release systems.
• Bilayer or multilayer tablets.
• Unit-dose packaging with stability advantages.
• Moisture-protective formulations.
• Pediatric or geriatric dosage forms.
• Fixed-dose combinations with another antihypertensive.

A conventional immediate-release tablet with standard excipients is unlikely to support a durable, high-value formulation patent unless it demonstrates a specific technical effect, such as improved stability, dissolution, content uniformity, or patient administration.

Which excipients are used in lisinopril/hydrochlorothiazide tablets?

Excipients vary by manufacturer and strength. Typical categories include fillers, binders, disintegrants, lubricants, glidants, and colorants.

Common excipient classes

Excipient function	Common options	Commercial purpose
Diluent or filler	Microcrystalline cellulose, mannitol, lactose, dibasic calcium phosphate, pregelatinized starch	Provides tablet mass and improves compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes breakup and dissolution
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces tooling friction and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Colorant	Iron oxides, approved lake colors	Supports strength identification and branding
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves appearance, handling, and identification

The selected excipient system must accommodate two active ingredients with different physical and chemical properties. Lisinopril is commonly supplied as lisinopril dihydrate and is highly water-soluble. HCTZ has substantially lower aqueous solubility. The resulting formulation challenge is not simply tablet manufacture; it is achieving consistent distribution and dissolution for both components across the full strength range.

How should the excipient strategy address lisinopril and HCTZ compatibility?

The optimal excipient strategy uses a low-moisture, robust direct-compression or dry-granulation platform unless development data support wet granulation.

Moisture control

Moisture management is central. Lisinopril-containing formulations require control of water activity and storage humidity because moisture can affect chemical stability, powder flow, granule properties, and tablet hardness. HCTZ also requires dissolution and stability monitoring in the selected matrix.

Practical controls include:

• Low-moisture excipients.
• Moisture-barrier film coatings.
• High-density polyethylene bottles with desiccant where justified.
• Aluminum-aluminum blister packaging for higher barrier protection.
• Tight control of granulation endpoint if wet processing is used.
• Stability testing under ICH long-term and accelerated conditions.[2]

A dry process can reduce hydrolytic exposure and simplify scale-up. Direct compression can lower manufacturing cost but requires excellent flow, segregation control, and content-uniformity performance.

Segregation and content uniformity

The combination contains a relatively low dose of lisinopril compared with the total tablet weight. Differences in particle size, density, morphology, and electrostatic behavior can cause segregation between lisinopril, HCTZ, and excipients.

The development program should evaluate:

• Particle-size distribution of both active ingredients.
• Ordered mixing or carrier-based blending.
• Blend uniformity at commercial scale.
• Hopper and feeder segregation.
• Assay and content uniformity by strength.
• Tablet weight variation.
• Compression-force effects on dissolution.

A formulation that performs well in laboratory blending can fail during transfer, storage, hopper discharge, or high-speed compression.

Dissolution balancing

HCTZ is the more likely dissolution constraint. Excessive hydrophobic lubrication, particularly over-lubrication with magnesium stearate, can slow wetting and dissolution. Excessive compression force can create hard tablets with delayed disintegration.

A balanced system may use:

• Crospovidone or croscarmellose sodium for rapid tablet breakup.
• Controlled lubricant concentration and mixing time.
• A hydrophilic filler or wetting-supportive excipient.
• Particle-size control for HCTZ.
• Coating weight limits that do not delay release.
• A dissolution method that discriminates between formulation variants.

The target is not simply rapid dissolution. It is reproducible release of both actives within the approved product profile.

What excipient platform offers the best commercial opportunity?

A direct-compression platform usually offers the strongest cost position for standard generic tablets, while dry granulation provides more flexibility when flow or segregation is problematic.

Direct compression

Direct compression is attractive because it reduces processing steps, equipment requirements, solvent exposure, and batch-cycle time. It works best when the active ingredients and excipients have compatible flow and compression properties.

Potential advantages include:

• Lower conversion cost.
• Shorter manufacturing cycle.
• Reduced water exposure.
• Easier scale-up.
• Lower cleaning burden.
• Greater flexibility for multiple strengths.

The principal risks are blend segregation, poor tablet weight control, capping, and variable dissolution.

Dry granulation

Roller compaction or slugging can improve flow, density, and content uniformity. It is useful when the active ingredients have poor flow or when the blend requires better handling at high speed.

The risks include over-compaction, reduced tabletability after milling, fines generation, and altered dissolution. Process development must control ribbon density, milling conditions, granule-size distribution, and compression force.

Wet granulation

Wet granulation may improve uniformity and tablet strength but adds water, drying, process time, and stability complexity. It is most defensible when direct compression and dry granulation cannot provide acceptable uniformity or dissolution.

For a low-margin mature generic, wet granulation is usually less attractive unless it solves a clear technical problem.

What formulation opportunities can differentiate lisinopril/hydrochlorothiazide?

The largest opportunities are in usability, packaging, and supply-chain performance rather than novel pharmacology.

Orally disintegrating and geriatric formulations

Hypertension prevalence is high among older adults, including patients with dysphagia or complex medication regimens. An orally disintegrating tablet could provide a patient-convenience advantage, but it would require careful evaluation of:

• Taste and mouthfeel.
• Lisinopril and HCTZ stability in a porous matrix.
• Humidity sensitivity.
• Mechanical strength.
• Packaging barrier performance.
• Dose accuracy across strengths.
• Bioequivalence and dissolution.

Mannitol-based platforms, crospovidone, and low-moisture processing are potential design directions. Taste masking may be required because both active ingredients can produce an unpleasant oral experience.

Low-cost, low-complexity standard tablets

The largest near-term opportunity is often a reliable standard tablet with:

• A short manufacturing cycle.
• High yield.
• Low reject rates.
• Broad excipient availability.
• Stable supply during API or excipient disruptions.
• Packaging appropriate for high-volume pharmacy distribution.

For a mature combination, a 1% to 2% manufacturing-cost advantage can matter more than a complex formulation patent.

Unit-dose and adherence packaging

Calendar blister packaging, 30-day unit-dose packs, and institutional packaging can improve dispensing efficiency and medication adherence. These approaches may be commercially useful for:

• Medicare and retail pharmacy channels.
• Long-term-care facilities.
• Government tenders.
• Hospital formularies.
• Mail-order fulfillment.

The packaging format must preserve stability and avoid creating a higher cost base than the market can support.

Gluten-free, lactose-free, and colorant-free products

Excipient simplification can create niche positioning. Lactose-free formulations may appeal to patients who avoid lactose-containing products. Colorant-free tablets can support a clean-label strategy. Gluten-free labeling requires validated control of materials and manufacturing processes.

These claims are commercially useful only if supported by quality systems and if the target channel values them. They rarely justify a premium in the broad generic market by themselves.

How strong is the patent estate for lisinopril/hydrochlorothiazide?

The core patent estate is weak for a conventional product because the relevant active-ingredient and original-product protections are expired. A new entrant’s defensibility must come from execution, formulation know-how, regulatory differentiation, or distribution.

Protection category	Strength for standard product
Lisinopril composition patent	Expired
HCTZ composition patent	Expired or commercially irrelevant
Original fixed-dose combination protection	Expired
Standard immediate-release formulation	Low
Novel ODT or taste-masked formulation	Potentially moderate, if technically supported
Manufacturing process know-how	Moderate but difficult to enforce
Packaging and stability system	Moderate commercial value
Brand and channel relationships	Potentially high in selected markets

Process know-how can be valuable even without a strong patent. Examples include a blending sequence that prevents segregation, a controlled dry-granulation process, a low-moisture coating system, or a packaging configuration that extends shelf life.

Which companies are challenging or supplying the market?

The U.S. market has historically included products from multiple generic manufacturers, contract manufacturers, and authorized distributors. Suppliers have included large generic companies such as Teva, Lupin, Zydus, Sandoz, and other ANDA holders, although active marketing status can change by manufacturer, strength, and time.

The competitive structure is fragmented. Buyers typically compare:

• Wholesale acquisition cost.
• Product availability.
• Number of approved strengths.
• Back-order history.
• Bottle and blister configurations.
• Recall record.
• Manufacturing-site reliability.
• State and federal contracting access.

FDA approval alone does not ensure commercial success. A supplier that can maintain all major strengths and avoid stock interruptions can gain share in a mature category without a novel formulation.

What generic launch scenarios exist?

Low-cost immediate-release launch

This is the most practical route. The product uses a conventional excipient system, standard tablet coating, and high-volume manufacturing. Success depends on cost, approval timing, and reliable supply.

Differentiated excipient launch

A product may use a lactose-free, colorant-free, low-moisture, or improved-dissolution platform. This can support targeted contracting or pharmacy-channel differentiation but usually does not create broad market exclusivity.

Orally disintegrating tablet launch

An ODT could target patients with swallowing difficulty and create a stronger formulation position. It would face higher development, packaging, taste, and regulatory costs. Commercial value depends on whether the product can obtain favorable reimbursement and demonstrate adequate demand.

International-market launch

Markets outside the United States may offer opportunities where fewer suppliers serve specific strengths or where local manufacturing is favored. Requirements differ across jurisdictions, including bioequivalence, impurity limits, excipient permissions, serialization, and packaging standards.

What patent litigation and settlement risks affect the product?

Current litigation risk for a conventional lisinopril/HCTZ generic is expected to be low relative to recently launched products. Historical disputes would be more relevant to the original branded launch period than to present-day generic entry.

A novel formulation could create new risks if it claims:

• A specific excipient ratio.
• A moisture-control system.
• A novel release profile.
• A taste-masking technology.
• A pediatric or geriatric use.
• A new combination with another active ingredient.

For standard products, the principal legal risks are more likely to involve manufacturing quality, labeling, product liability, supply contracts, trademark issues, or regulatory enforcement than Paragraph IV patent litigation.

What is the revenue exposure and commercial value?

Lisinopril/hydrochlorothiazide is a high-volume, low-price category. Revenue exposure is usually meaningful through unit volume but limited on a per-tablet basis. A manufacturer’s economics depend on scale, procurement, channel mix, and product availability.

The strongest commercial opportunities are:

1. High-volume, low-cost production of the principal strengths.
2. Reliable supply to pharmacy chains and government tenders.
3. Multi-strength portfolios using one common manufacturing platform.
4. Improved packaging for adherence and institutional dispensing.
5. Selective ODT or dysphagia-focused development.
6. Contract manufacturing using flexible, low-moisture tablet technology.
7. International supply where local competition is less intense.

A single-strength launch is less attractive than a platform covering 10/12.5 mg, 20/12.5 mg, and 20/25 mg. Common tooling, coating, packaging, and analytical methods can reduce lifecycle cost.

How does lisinopril/hydrochlorothiazide compare with other antihypertensive combinations?

Compared with newer branded combinations, lisinopril/HCTZ has a weaker patent position and lower pricing. Its advantages are clinical familiarity, established dosing, broad generic availability, and relatively simple oral solid-dose manufacturing.

Combination	Patent and commercial profile	Excipient opportunity
Lisinopril/HCTZ	Mature, low-cost, multisource	Cost reduction, stability, ODT, packaging
Losartan/HCTZ	Mature generic combination	Similar manufacturing and adherence opportunities
Amlodipine/benazepril	Mature combination with different formulation needs	Capsule or tablet platform, dissolution control
Olmesartan/HCTZ	Mature but may have stronger brand-market positioning in some regions	Stability and differentiated packaging
Sacubitril/valsartan	More complex and historically stronger exclusivity	Higher-value but materially different patent and regulatory risk

Lisinopril/HCTZ is most attractive to companies with efficient generic manufacturing and established pharmacy or institutional distribution, not to companies seeking long-duration exclusivity from the base product.

Key Takeaways

• Lisinopril/hydrochlorothiazide is an established immediate-release generic combination with no meaningful biosimilar issue.
• Core composition and original-product patent protections are expired or commercially irrelevant.
• The main technical challenge is controlling blend uniformity, moisture exposure, and HCTZ dissolution.
• Direct compression offers the strongest cost opportunity when flow and segregation are controlled.
• Dry granulation is a useful alternative for improving powder handling and content uniformity.
• ODT, taste-masked, geriatric, and adherence-oriented products offer the clearest formulation differentiation.
• Low-moisture excipients and barrier packaging can improve stability and reduce quality risk.
• Commercial success depends on multi-strength supply, low manufacturing cost, and reliable distribution.
• Conventional products face limited Paragraph IV and litigation exposure.
• A novel formulation may create new patent value but also introduces higher development and regulatory costs.

FAQs

Is lisinopril/hydrochlorothiazide still protected by active patents?

The core active ingredients and original fixed-dose combination have been off patent for many years. New patents may apply only to separately developed formulations, delivery systems, or manufacturing processes.

Which excipient is best for improving HCTZ dissolution?

No single excipient is universally optimal. Crospovidone, croscarmellose sodium, hydrophilic fillers, controlled particle size, and limited lubricant exposure are common development tools. Performance must be confirmed through comparative dissolution and stability testing.

Can lisinopril/hydrochlorothiazide be developed as an orally disintegrating tablet?

Yes. An ODT is technically feasible, but taste, humidity sensitivity, mechanical strength, packaging, and bioequivalence create the main development hurdles.

Does a lactose-free lisinopril/HCTZ tablet create a strong market advantage?

It can support targeted differentiation for patients and channels that avoid lactose, but it generally does not create broad pricing power or meaningful market exclusivity.

What is the highest-value manufacturing technology for this combination?

A scalable low-moisture direct-compression process is usually the most attractive starting point. Dry granulation becomes more valuable when powder flow, segregation, or high-speed compression performance is inadequate.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

2. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

4. National Library of Medicine. (2024). DailyMed: Lisinopril and hydrochlorothiazide labeling. U.S. National Library of Medicine.

5. U.S. Food and Drug Administration. (1997). Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. FDA.